Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature

Drug Delivery and Translational Research

Volumn 5, Issue 4, 2015, Pages 360-371

  Vassilieva, Elena V ^a   Kalluri, Haripriya ^b   McAllister, Devin ^b   Taherbhai, Misha T ^a   Esser, E Stein ^a   Pewin, Winston P ^b   Pulit Penaloza, Joanna A ^a,c   Prausnitz, Mark R ^b   Compans, Richard W ^a   Skountzou, Ioanna ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Dissolving microneedle patches; Influenza vaccines; Metal microneedle arrays; Mouse model; Skin immunization

Indexed keywords

GELATIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISSOLVING MICRONEEDLE PATCH; DRUG DOSAGE FORM COMPARISON; DRUG STABILITY; DRUG STORAGE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNODIFFUSION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MICRONEEDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; SEASONAL INFLUENZA; STORAGE TEMPERATURE; TRANSDERMAL PATCH; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROINJECTION; ORTHOMYXOVIRIDAE INFECTIONS; TEMPERATURE; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MICROINJECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; TEMPERATURE; TRANSDERMAL PATCH;

EID: 84938781226     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0228-0     Document Type: Article

References (62)

1. del Pilar Martin M, Weldon WC, Zarnitsyn VG, Koutsonanos DG, Akbari H, Skountzou I, et al. Local response to microneedle-based influenza immunization in the skin. mBio. 2012;3(2):e00012–12. doi:10.1128/mBio.00012-12.
2. Chen X, Fernando GJ, Raphael AP, Yukiko SR, Fairmaid EJ, Primiero CA, et al. Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. J Control Release Off J Control Release Soc. 2012;158(1):78–84. doi:10.1016/j.jconrel.2011.10.026.
3. Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, et al. A protective role of murine langerin(+) cells in immune responses to cutaneous vaccination with microneedle patches. Sci Rep. 2014;4:6094. doi:10.1038/srep06094.
4. Quinn HL, Kearney MC, Courtenay AJ, McCrudden MT, Donnelly RF. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv. 2014;11(11):1769–80. doi:10.1517/17425247.2014.938635.
5. Skountzou I, Compans RW. Skin immunization with influenza vaccines. Curr Top Microbiol Immunol. 2015;386:343–69. doi:10.1007/82_2014_407.
6. Levin Y, Kochba E, Hung I, Kenney R. Intradermal vaccination using the novel microneedle device MicronJet600: past, present and future. Hum Vaccines Immunother. 2015. doi:10.1080/21645515.2015.1010871.
7. Barkam S, Saraf S, Seal S. Fabricated micro-nano devices for in vivo and in vitro biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(6):544–68. doi:10.1002/wnan.1236.
8. Jin J, Reese V, Coler R, Carter D, Rolandi M. Chitin microneedles for an easy-to-use tuberculosis skin test. Adv Healthcare Mater. 2014;3(3):349–53. doi:10.1002/adhm.201300185.
9. Paliwal S, Hwang BH, Tsai KY, Mitragotri S. Diagnostic opportunities based on skin biomarkers. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2013;50(5):546–56. doi:10.1016/j.ejps.2012.10.009.
10. Koutsonanos DG, Compans RW, Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol. 2013;785:121–32. doi:10.1007/978-1-4614-6217-0_13.
11. Qiu Y, Guo L, Zhang S, Xu B, Gao Y, Hu Y et al. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Delivery. 2015:1–8. doi:10.3109/10717544.2014.992497.
12. Carey JB, Vrdoljak A, O’Mahony C, Hill AV, Draper SJ, Moore AC. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Rep. 2014;4:6154. doi:10.1038/srep06154.
13. van der Maaden K, Trietsch SJ, Kraan H, Varypataki EM, Romeijn S, Zwier R, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res. 2014;31(7):1846–54. doi:10.1007/s11095-013-1288-9.
14. Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, Raphael AP, et al. Nanopatch-targeted skin vaccination against West Nile virus and Chikungunya virus in mice. Small. 2010;6(16):1776–84. doi:10.1002/smll.201000331.
15. Suh H, Shin J, Kim YC. Microneedle patches for vaccine delivery. Clin Exp Vaccine Res. 2014;3(1):42–9. doi:10.7774/cevr.2014.3.1.42.
16. Hirobe S, Azukizawa H, Matsuo K, Zhai Y, Quan YS, Kamiyama F, et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res. 2013;30(10):2664–74. doi:10.1007/s11095-013-1092-6.
17. Gill HS, Prausnitz MR. Pocketed microneedles for drug delivery to the skin. J Phys Chem Solids. 2008;69(5–6):1537–41. doi:10.1016/j.jpcs.2007.10.059.
18. Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices. 2009;11(1):35–47. doi:10.1007/s10544-008-9208-1.
19. Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release Off J Control Release Soc. 2011;154(2):148–55. doi:10.1016/j.jconrel.2011.05.021.
20. Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 2014. doi:10.1016/j.vaccine.2014.01.076.
21. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A. 2009;106(19):7968–73. doi:10.1073/pnas.0812652106.
22. Koutsonanos DG, del Pilar MM, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infec Dis. 2011;204(4):582–91. doi:10.1093/infdis/jir094.
23. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol CVI. 2011;18(4):647–54. doi:10.1128/CVI.00435-10.
24. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep. 2012;2:357. doi:10.1038/srep00357.
25. Song JM, Kim YC OE, Compans RW, Prausnitz MR, Kang SM. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther J Am Soc Gene Ther. 2012;20(7):1472–80. doi:10.1038/mt.2012.69.
26. Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010;84(15):7760–9. doi:10.1128/JVI.01849-09.
27. Fernando GJ, Chen X, Primiero CA, Yukiko SR, Fairmaid EJ, Corbett HJ, et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release Off J Control Release Soc. 2012;159(2):215–21. doi:10.1016/j.jconrel.2012.01.030.
28. Xie H, Jing X, Li X, Lin Z, Plant E, Zoueva O, et al. Immunogenicity and cross-reactivity of 2009–2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS ONE. 2011;6(1):e16650. doi:10.1371/journal.pone.0016650.
29. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246–51. doi:10.1016/j.vaccine.2014.06.052.
30. Kang SM, Song JM, Kim YC. Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines. 2012;11(5):547–60. doi:10.1586/erv.12.25.
31. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198(5):650–8. doi:10.1086/590434.
32. Duggan ST, Plosker GL. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged > or = 60 years). Drugs Aging. 2010;27(7):597–605. doi:10.2165/11203880-000000000-00000.
33. Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine. 2008;26(22):2700–5. doi:10.1016/j.vaccine.2008.03.016.
34. Wong YL, Sampson S, Germishuizen WA, Goonesekera S, Caponetti G, Sadoff J, et al. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A. 2007;104(8):2591–5. doi:10.1073/pnas.0611430104.
35. Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD, Lechuga-Ballesteros D, et al. Heat-stable measles vaccine produced by spray drying. Vaccine. 2010;28(5):1275–84. doi:10.1016/j.vaccine.2009.11.024.
36. Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J, et al. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method. Vaccine. 2010;28(31):5093–9. doi:10.1016/j.vaccine.2010.04.112.
37. Soema PC, Willems GJ, van Twillert K, van de Wijdeven G, Boog CJ, Kersten GF, et al. Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses. PLoS ONE. 2014;9(3), e92806. doi:10.1371/journal.pone.0092806.
38. Frolov VG, Seid Jr RC, Odutayo O, Al-Khalili M, Yu J, Frolova OY, et al. Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respir Viruses. 2008;2(2):53–60. doi:10.1111/j.1750-2659.2008.00040.x.
39. Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJ, Kendall MA. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small. 2010;6(16):1785–93. doi:10.1002/smll.201000326.
40. Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O’Hagan DT. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 2012;101(3):1021–7. doi:10.1002/jps.23019.
41. Matsuo K, Hirobe S, Yokota Y, Ayabe Y, Seto M, Quan YS, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release Off J Control Release Soc. 2012;160(3):495–501. doi:10.1016/j.jconrel.2012.04.001.
42. Sharma M, Brahmne H, Bafna P. Potency testing of novel DTP group of vaccines. Int J Compr Pharmacol. 2011;11(2):1–9.
43. Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O’Hagan DT. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 2011. doi:10.1002/jps.23019.
44. WHO/CDS/CSR/NCS. WHO manual of animal influenza diagnosis and surveillance. Department of Communicable Disease Surveillance and Response. 2002.
45. Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol. 2007;81(3):1083–94. doi:10.1128/JVI.01692-06.
46. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–7.
47. Sha Z, Compans RW. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol. 2000;74(11):4999–5005.
48. Kommareddy S, Bonificio A, Gallorini S, Baudner B, Singh M, O’Hagan D. Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. J Pharm Sci. 2013;102(3):866–75. doi:10.1002/jps.23444.
49. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release Off J Control Release Soc. 2007;117(2):227–37. doi:10.1016/j.jconrel.2006.10.017.
50. Koutsonanos DG, del Pilar MM, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE. 2009;4(3), e4773. doi:10.1371/journal.pone.0004773.
51. Fischer K. Neues verfahren zur maßanalytischen bestimmung des wassergehaltes von flüssigkeiten und festen körpern. Angew Chem. 1935;48(26):394–6. doi:10.1002/ange.19350482605.
52. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand. 1977;5(3):237–47.
53. Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol. 1993;37(3–4):253–62.
54. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915–20. doi:10.1038/nm.2182.
55. Prevention CfDCa. Epidemiology and prevention of vaccine-preventable diseases the pink book: course textbook. In: Atkinson WWS, Hamborsky J, editors. 12th edition, second printing. Washington DC: Public Health Foundation; 2012.
56. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis Off publ Infect Dise Soc Am. 2012;54(10):1427–36. doi:10.1093/cid/cis211.
57. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child. 1990;144(5):595–600.
58. Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol CVI. 2012;19(6):897–908. doi:10.1128/CVI.05726-11.
59. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect Dis. 2006;194(8):1032–9. doi:10.1086/507309.
60. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release Off J Control Release Soc. 2010;142(2):187–95. doi:10.1016/j.jconrel.2009.10.013.
61. Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. PLoS ONE. 2013;8(6):e66312. doi:10.1371/journal.pone.0066312.
62. Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Masseoud F, et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol. 2010;185(3):1642–9. doi:10.4049/jimmunol.1000091.